For Forest, No Single Silver Bullet But Many Opportunities
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
There is no quick fix to guide Forest Laboratories through 2012, when its best seller, the antidepressant Lexapro, goes off patent. But management thinks it will have enough patches in place by then to compensate for lost revenues and avert disaster.